HFE mutations and risk of coronary heart disease in middle‐aged women

Background  Although heterozygosity for the C282Y mutation in the HFE gene has been associated with an increased risk of cardiovascular events, epidemiological studies remain inconclusive. The aim of the present study was to obtain further evidence as to whether HFE mutations are associated with risk of coronary heart disease (CHD) in middle‐aged women. We used data of a cohort of 15 236 Dutch middle‐aged women to investigate whether C282Y carriers and H63D carriers are at increased risk of coronary heart disease compared with non‐carriers.

[1]  F. Schmidt.  Meta-Analysis , 2008 .

[2]  D. van der A,et al.  HFE genotypes and dietary heme iron: no evidence of strong gene-nutrient interaction on serum ferritin concentrations in middle-aged women. , 2006, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[3]  B. Nordestgaard,et al.  Hereditary Hemochromatosis and Risk of Ischemic Heart Disease: A Prospective Study and a Case-Control Study , 2005, Circulation.

[4]  Kappelle Lj.  [Primary prevention of cardiovascular disease with acetylsalicylic acid: in high-risk patients]. , 2005 .

[5]  L. Kappelle.  [Primary prevention of cardiovascular disease with acetylsalicylic acid: in high-risk patients]. , 2005, Nederlands tijdschrift voor geneeskunde.

[6]  M. Worwood,et al.  Heterozygosity for the haemochromatosis mutation HFE C282Y is not a risk factor for angina , 2004, Heart.

[7]  F. Muskiet,et al.  Curaçao patients with coronary artery disease have a higher prevalence of the HFE C282Y mutation. , 2004, The West Indian medical journal.

[8]  Ian Purvis,et al.  Detection of genotyping errors by Hardy–Weinberg equilibrium testing , 2004, European Journal of Human Genetics.

[9]  C. Packard,et al.  Haemochromatosis gene mutations and risk of coronary heart disease: a west of Scotland coronary prevention study (WOSCOPS) substudy , 2004, Heart.

[10]  R. Bolli.  Oxygen-derived free radicals and myocardial reperfusion injury: An overview , 1991, Cardiovascular Drugs and Therapy.

[11]  E. Riboli,et al.  Prospect-EPIC Utrecht: Study design and characteristics of the cohort population , 2004, European Journal of Epidemiology.

[12]  A. Nissinen,et al.  Cardiovascular risk factors as determinants of 25-year all-cause mortality in the seven countries study , 2004, European Journal of Epidemiology.

[13]  L. Szweda,et al.  Cardiac ischemia/reperfusion, aging, and redox-dependent alterations in mitochondrial function. , 2003, Archives of biochemistry and biophysics.

[14]  T. McDonagh,et al.  The prevalence of haemochromatosis gene mutations in the West of Scotland and their relation to ischaemic heart disease , 2003, Heart.

[15]  F. Licastro,et al.  Association between HFE mutations and acute myocardial infarction: a study in patients from Northern and Southern Italy. , 2003, Blood cells, molecules & diseases.

[16]  H. Sigusch,et al.  Haemochromatosis (HFE) gene C282Y mutation and the risk of coronary artery disease and myocardial infarction: a study in 1279 patients undergoing coronary angiography , 2003, Journal of medical genetics.

[17]  V. Felitti,et al.  Haematological effects of the C282Y HFE mutation in homozygous and heterozygous states among subjects of northern and southern European ancestry , 2003, British journal of haematology.

[18]  A. Hofman,et al.  A population-based study of the effect of the HFE C282Y and H63D mutations on iron metabolism , 2003, European Journal of Human Genetics.

[19]  V. Felitti,et al.  Prevalence of coronary heart disease associated with HFE mutations in adults attending a health appraisal center. , 2002, The American journal of medicine.

[20]  M. Knuiman,et al.  Effects of Body Iron Stores and Haemochromatosis Genotypes on Coronary Heart Disease Outcomes in the Busselton Health Study , 2002, Journal of cardiovascular risk.

[21]  P. H. Moghaddam,et al.  No increase in mortality and morbidity among carriers of the C282Y mutation of the hereditary haemochromatosis gene in the oldest old: the Leiden 85‐plus Study , 2002, European journal of clinical investigation.

[22]  R. Wood.  The "anemic" enterocyte in hereditary hemochromatosis: molecular insights into the control of intestinal iron absorption. , 2002, Nutrition reviews.

[23]  E. Trabetti,et al.  Biochemical and genetic markers of iron status and the risk of coronary artery disease: an angiography-based study. , 2002, Clinical chemistry.

[24]  J. Olynyk,et al.  A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. , 2002, Gastroenterology.

[25]  B. Meyer,et al.  Haemochromatosis mutations and ferritin in myocardial infarction: a case‐control study , 2002, European journal of clinical investigation.

[26]  M. Kruszewski,et al.  Further evidence that oxidative stress may be a risk factor responsible for the development of atherosclerosis. , 2001, Free radical biology & medicine.

[27]  W. Burke,et al.  HFE gene and hereditary hemochromatosis: a HuGE review. Human Genome Epidemiology. , 2001, American journal of epidemiology.

[28]  D. Arveiler,et al.  Association studies between haemochromatosis gene mutations and the risk of cardiovascular diseases , 2001, European journal of clinical investigation.

[29]  J H Eckfeldt,et al.  A prospective study of coronary heart disease and the hemochromatosis gene (HFE) C282Y mutation: the Atherosclerosis Risk in Communities (ARIC) study. , 2001, Atherosclerosis.

[30]  Marx,et al.  Biochemical expression of heterozygous hereditary hemochromatosis. , 2000, European journal of internal medicine.

[31]  J. Beilby,et al.  Serum Ferritin and C282Y Mutation of the Hemochromatosis Gene as Predictors of Asymptomatic Carotid Atherosclerosis in a Community Population , 2000, Stroke.

[32]  M. Margaglione,et al.  Risk of Myocardial Infarction in Carriers of Mutations in the Hemochromatosis-associated Gene , 2000, Thrombosis and Haemostasis.

[33]  M. Arca,et al.  Haemochromatosis gene mutations and risk of coronary artery disease , 2000, European Journal of Human Genetics.

[34]  M. Zago,et al.  HFE gene mutations in coronary atherothrombotic disease. , 2000, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[35]  J. Ramires,et al.  C282Y mutation in the HLA-H Gene is Not a Risk Factor for Patients with Myocardial Infarction , 2000, Journal of cardiovascular risk.

[36]  E. Vartiainen,et al.  Cardiovascular diseases and risk factors in Finland. , 1999, Preventive medicine.

[37]  E. Ford,et al.  Diabetes and serum ferritin concentration among U.S. adults. , 1999, Diabetes care.

[38]  A. Looker,et al.  Iron status and the risk of coronary heart disease. , 1999, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[39]  J. Sixma,et al.  Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women. , 1999, Circulation.

[40]  T. Lakka,et al.  Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation : a prospective cohort study in men in eastern Finland. , 1999, Circulation.

[41]  J. Marx,et al.  Iron, atherosclerosis, and ischemic heart disease. , 1999, Archives of internal medicine.

[42]  A. Hofman,et al.  Serum ferritin and risk of myocardial infarction in the elderly: the Rotterdam Study. , 1999, The American journal of clinical nutrition.

[43]  E. Marbán,et al.  Molecular and cellular mechanisms of myocardial stunning. , 1999, Physiological reviews.

[44]  J. Danesh,et al.  Coronary heart disease and iron status: meta-analyses of prospective studies. , 1999, Circulation.

[45]  Trip,et al.  Prevalence of hereditary haemochromatosis in premature atherosclerotic vascular disease , 1998, British journal of haematology.

[46]  I. Bata,et al.  Relation of HFE gene mutations, high iron stores and early onset coronary artery disease. , 1998, The Canadian journal of cardiology.

[47]  M. C. Ellis,et al.  A novel MHC class I–like gene is mutated in patients with hereditary haemochromatosis , 1996, Nature Genetics.

[48]  J. Berliner,et al.  The role of oxidized lipoproteins in atherogenesis. , 1996, Free radical biology & medicine.

[49]  M. Dufour,et al.  Epidemiology. Introduction. , 1995, Recent developments in alcoholism : an official publication of the American Medical Society on Alcoholism, the Research Society on Alcoholism, and the National Council on Alcoholism.

[50]  B. Stricker,et al.  Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. , 1992, Journal of epidemiology and community health.

[51]  H. G. van Eijk,et al.  Iron-load increases the susceptibility of rat hearts to oxygen reperfusion damage. Protection by the antioxidant (+)-cyanidanol-3 and deferoxamine. , 1988, Circulation.

[52]  M. Weisfeldt,et al.  Improvement of postischemic myocardial function and metabolism induced by administration of deferoxamine at the time of reflow: the role of iron in the pathogenesis of reperfusion injury. , 1987, Circulation.

[53]  R. L. Prentice,et al.  A case-cohort design for epidemiologic cohort studies and disease prevention trials , 1986 .

[54]  J. Sullivan.  IRON AND THE SEX DIFFERENCE IN HEART DISEASE RISK , 1981, The Lancet.

[55]  G. Hardy.  MENDELIAN PROPORTIONS IN A MIXED POPULATION. , 1908 .